Know Cancer

or
forgot password

Phase 4, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Induction Agents, Alemtuzumab, Basiliximab or Rabbit Anti-thymocyte Globulin in Combination With Tacrolimus, MMF, and a Rapid Steroid Withdrawal in Renal Transplant Recipients


Phase 4
18 Years
N/A
Not Enrolling
Both
Kidney Transplantation

Thank you

Trial Information

Phase 4, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Induction Agents, Alemtuzumab, Basiliximab or Rabbit Anti-thymocyte Globulin in Combination With Tacrolimus, MMF, and a Rapid Steroid Withdrawal in Renal Transplant Recipients


A 2 arm (1 Active, 1 Active Control) study is to compare the safety and efficacy of
different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in
renal transplant recipients treated with tacrolimus, MMF and a rapid steroid withdrawal.


Inclusion Criteria:



- Recipient of a primary or re-transplanted deceased donor kidney or a primary or
re-transplanted non-human leukocyte antigen (HLA) living donor kidney (ie., HLA
identical or 0 antigen mismatch deceased donor kidneys are allowed).

Exclusion Criteria:

- Patient has previously received an organ transplant other than a kidney

- Patient receiving chronic steroid therapy at time of transplant

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Patient Incidence of Biopsy-confirmed Acute Rejection (BCAR) at 6 Months

Outcome Description:

A BCAR is a suspected new rejection w/in 6 mos. of skin closure, confirmed by Banff Grade ≥1A assigned by a pathologist. The Banff 97 classification system is used for interpreting histology of allograft biopsies, including Mild (1A/1B), Moderate (2A/2B) & Severe (3). Kaplan Meier analysis was used to estimate % of pts. w/event. Patients w/no event at time of scheduled visit or whose 1st event was after premature discontinuation of study drug/tacrolimus were censored on the scheduled day of a) assessment, b) of premature treatment discontinuation or c) last evaluation, whichever came 1st.

Outcome Time Frame:

6 months

Safety Issue:

No

Principal Investigator

Central Contact

Investigator Role:

Study Director

Investigator Affiliation:

Astellas Pharma Global Development

Authority:

United States: Institutional Review Board

Study ID:

20-04-003

NCT ID:

NCT00113269

Start Date:

May 2005

Completion Date:

March 2009

Related Keywords:

  • Kidney Transplantation
  • Treatment Effectiveness
  • Treatment Efficacy
  • Anti-rejection therapy
  • Immunosuppression
  • Therapy, antirejection
  • Renal Transplantation
  • Transplantation, Kidney
  • Transplantation, Renal
  • Grafting, Kidney

Name

Location

Hinsdale, Illinois  60521
Birmingham, Alabama  35294
Fountain Valley, California  92708
Miami, Florida  33176
Albany, New York  12208
Cleveland, Ohio  44195
Philadelphia, Pennsylvania  19104
Austin, Texas  78705
Hackensack, New Jersey  07601
Denver, Colorado  
Charlotte, North Carolina  
Eugene, Oregon  
Milwaukee, Wisconsin  
Charleston, South Carolina  
Washington, District of Columbia  
Salt Lake City, Utah  84112